Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BOSUTINIB MONOTHERAPY IN JAPANESE ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA

NCT03128411 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03128411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03128411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BOSUTINIB MONOTHERAPY IN JAPANESE ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
May 15, 2017
Completion date
March 4, 2021
Enrollment
64 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, chronic myelogenous